Clinical trials
Rituximab clinical trials
Below are recruiting rituximab clinical trials, each written for real people, not researchers. We’re tracking 279 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06682169RecruitingPhase 3
New pill for chronic graft-versus-host disease after other treatments fail
This trial tests a new pill called rovadicitinib for chronic GVHD that has not improved after 2 to 5 other treatments. It compares the new drug to one chosen by your doctor from a list of approved options.
Hefei, AnhuiAges 18–70 - NCT06704555RecruitingPhase 2
Radiation plus drug combo for untreated bulky follicular lymphoma
This trial tests a combination of radiation, an immunotherapy drug (tislelizumab), and chemotherapy (RCHOP) for people with previously untreated bulky follicular lymphoma. It aims to see if giving radiation first followed by the drug combo can improve outcomes for larger tumors.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT05091424RecruitingPhase 1
Mosunetuzumab with or without venetoclax for CLL
This Phase 1 study tests whether mosunetuzumab alone or with venetoclax is safe and effective for people with chronic lymphocytic leukemia (CLL) that came back or did not respond to prior treatment. It may help by controlling the CLL immune system response while also studying dosing and side effects.
Rochester, MinnesotaAges 18 years+ - NCT05139017RecruitingPhase 2/Phase 3
Test drug Zilovertamab vedotin with standard care for lymphoma
This trial studies zilovertamab vedotin added to standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It may help by targeting lymphoma cells and improving how well standard treatment works after prior treatments have failed.
Glendale, ArizonaAges 18 years+ - NCT06756308RecruitingPhase 2
Enasidenib for IDH2-mutated T-cell lymphoma
This trial tests a drug called enasidenib for people with a rare type of T-cell lymphoma (AITL) that has a specific IDH2 gene mutation. The goal is to see if enasidenib can shrink tumors or slow the disease.
Boston, MassachusettsAges 18 years+ - NCT06765317RecruitingPhase 2
Glofitamab therapy for older adults with diffuse large B-cell lymphoma
This trial tests a new combination therapy using glofitamab for people aged 65 or older with diffuse large B-cell lymphoma who have not received prior treatment. The goal is to see if this approach is safe and effective for patients who are considered too frail for standard therapies.
Basking Ridge, New JerseyAges 65–80 - NCT06792253RecruitingPhase 3
BEBT-908 plus rituximab for relapsed large B-cell lymphoma
This study tests a new drug, BEBT-908, combined with rituximab for people with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment that included a CD20 antibody. The goal is to see if this new combination works better than standard care.
Beijing, Beijing MunicipalityAges 18–75 - NCT06803693RecruitingPhase 2
New drug combo for untreated large B-cell lymphoma
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06918431RecruitingPhase 2
Erwinia asparaginase with chemo for new ALL or LBL
This trial tests adding an asparaginase drug to standard chemotherapy for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The goal is to see if this combination improves outcomes.
Phoenix, ArizonaAges 18–54 - NCT06929624RecruitingPhase 3
Study of SHR-A1912 plus chemotherapy for DLBCL
This trial tests a new drug, SHR-A1912, combined with standard chemotherapy (R-GemOx) for people with diffuse large B-cell lymphoma (DLBCL) that has returned or not improved after at least one prior treatment. It aims to see if the combination works better than chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–80 - NCT06933134Recruiting
Using a biomarker to guide low-dose rituximab in rheumatoid arthritis
This trial aims to find out if a simple blood test (biomarker) can show whether a lower dose of rituximab will work for people with rheumatoid arthritis. If successful, it could help patients maintain good results with less medicine and fewer side effects.
ToursAges 18 years+ - NCT06954805RecruitingPhase 2
Study of ctDNA in PTLD after transplant
This trial looks at a blood test (ctDNA) to track post-transplant lymphoproliferative disorder (PTLD). It tests how well ctDNA measures treatment response and may help guide future care.
Stanford, CaliforniaAges 15 years+ - NCT06980584Recruiting
Treating nonthrombotic pulmonary hypertension from fibrosing mediastinitis
This study tests a treatment for a rare lung condition called fibrosing mediastinitis, where scar tissue in the chest presses on the lung artery, causing high blood pressure in the lungs. The goal is to see if the treatment can improve your symptoms and quality of life.
BeijingAges 18–85 - NCT06983821RecruitingPhase 3
Low-dose steroids for kidney disease from vasculitis
This trial tests lower steroid doses for people with certain types of vasculitis that have newly affected their kidneys. The goal is to find out if a lower dose works just as well with fewer side effects.
Hamilton, OntarioAges 18 years+ - NCT06991114RecruitingPhase 2
AlloNK and rituximab for relapsing rheumatologic diseases
This trial tests a new natural killer (NK) cell therapy called AlloNK given with rituximab for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, inflammatory myopathies, or systemic sclerosis) that have not responded well to standard treatments. The goal is to see if this combination can better control the disease.
Tuscaloosa, AlabamaAges 18 years+ - NCT07015242RecruitingPhase 2
Liso-cel for newly treated primary CNS lymphoma
This trial tests a new cancer immunotherapy called liso-cel (a CAR T-cell treatment) as a first treatment for people with primary CNS lymphoma who cannot have a stem cell transplant. If you've already received some high-dose methotrexate and your tumor responded, this study may offer a more targeted therapy to try to improve results.
Aurora, ColoradoAges 18 years+ - NCT07037732Recruiting
Monitoring rituximab in autoimmune diseases
This study looks at the levels of rituximab (a medicine that calms the immune system) and your body's response to it in people with certain autoimmune diseases. It may help doctors understand how to better adjust treatment.
Nice, Alpes MaritimesAges 18 years+ - NCT07038382RecruitingPhase 2
Study of HLX79 with Rituximab for Active Kidney Disease
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
BeijingAges 18–75 - NCT07072208Recruiting
A Study of Four Drugs for Older Adults with DLBCL
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
Suzhou, JiangsuAges 70 years+ - NCT07081022RecruitingPhase 2
Study of JS203 combination therapy for B-cell lymphoma
This trial tests a new combination treatment for a type of lymphoma (B-cell non-Hodgkin's lymphoma) that has a protein called CD20 on its cells. It may be an option if you have not received certain previous therapies and your lymphoma is measurable, to see if the combination can help control the disease.
Beijing, Beijing MunicipalityAges 18–80 - NCT07133113Recruiting
Effects of treatments in autoimmune encephalitis
This study follows patients with autoimmune encephalitis (brain inflammation caused by the immune system) to see how treatments affect them in the medium term. It may help doctors learn which treatments work best for people with this condition.
BronAges Any age - NCT07139873RecruitingPhase 3
Study of DZD8586 vs. standard care for relapsed CLL or SLL
This trial tests a new drug, DZD8586, against other standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to prior therapy. The goal is to see if DZD8586 works better or has fewer side effects.
Nanjing, JiangsuAges 18 years+ - NCT07189065RecruitingPhase 2
Rocbrutinib for relapsed or refractory non-GCB DLBCL
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
Hefei, AnhuiAges 18 years+ - NCT07189325RecruitingPhase 3
Comparing two ways to manage relapsing-remitting MS
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
MontpellierAges 40 years+
Hear when a new Rituximab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rituximab?
- Yes. Clin2 currently lists 279 recruiting rituximab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rituximab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rituximab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.